Preclinical evaluation of Amphihevir, a first-in-class clinical Hepatitis C virus NS4B inhibitor.

导出 OA

翻译打印收藏纠错

作者： Xin,Tao ^[1] ; Ningyu,Wang ^[2] ; Jianfei,Wang ^[3] ; Zhifei,Fu ^[3] ; Zhengxian,Gu ^[3] ; Yang,Zhang ^[3] ; Shuhui,Chen ^[3] ; Lichun,Wang ^[1] ; Luoting,Yu ^[4]

作者单位： State Key Laboratory of Biotherapy/Collaborative Innovation Center for Biotherapy, West China Hospital, West China Medical School, Sichuan University, Chengdu 610041, China. ^[1] School of Life Science and Engineering, Southwest JiaoTong University, Chengdu, China. ^[2] WuXi AppTec (Shanghai) Co., Ltd., Shanghai, China. ^[3] State Key Laboratory of Biotherapy/Collaborative Innovation Center for Biotherapy, West China Hospital, West China Medical School, Sichuan University, Chengdu 610041, China yuluot@scu.edu.cn. ^[4]

DOI 10.1128/AAC.01237-19

PMID 31527036

发布时间 2023-07-18

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交

浏览1

Antimicrobial agents and chemotherapy

2019年63卷12期

相似文献

中文期刊
外文期刊
学位论文
会议论文

检索历史清除

Preclinical evaluation of Amphihevir, a first-in-class clinical Hepatitis C virus NS4B inhibitor.

Antimicrobial agents and chemotherapy

相似文献

Antimicrobial agents and chemotherapy

相关期刊

参考文献：
指定格式：	NoteExpress EndNote RefWorks NoteFirst

检索历史 清除

Preclinical evaluation of Amphihevir, a first-in-class clinical Hepatitis C virus NS4B inhibitor.

Antimicrobial agents and chemotherapy

相似文献

Antimicrobial agents and chemotherapy

相关期刊

检索历史清除